Company news

Bionano Genomics, Inc. news in 2024

Bionano Genomics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway

December 30, 2024

Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis

December 22, 2024

Bionano Announces Presentations at the American Society of Hematology (ASH) Annual Meeting that Underscore OGM Utility Across Blood Cancer Research and Cell & Gene Therapy

December 9, 2024

Bionano Reports Third Quarter 2024 Results and Highlights Recent Business Progress

November 12, 2024

Bionano to Report Third Quarter 2024 Financial Results and Host a Conference Call and Webcast on November 13, 2024

November 6, 2024

Bionano Announces $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

October 30, 2024

Bionano Adjourns Special Meeting of Stockholders to November 27, 2024

October 30, 2024

Bionano Announces Publication Outlining Utility of OGM for Resolution of MYC Gene Rearrangements in Multiple Myeloma

October 23, 2024

Bionano Announces Preliminary 3Q 2024 Revenues and Cash

October 9, 2024

Bionano Adjourns Special Meeting of Stockholders to October 30, 2024

October 2, 2024

Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress

August 6, 2024

Bionano Announces Presentation of Optical Genome Mapping Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting

July 31, 2024

Bionano to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 7, 2024

July 30, 2024

Bionano Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma

July 22, 2024

Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

July 4, 2024

Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual Meeting

July 1, 2024

Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research

June 19, 2024

Bionano Laboratories Announces New Category I CPT Code for OGM Use in Hematological Malignancy Analysis

June 16, 2024

Bionano Announces Robust Presence at Upcoming Cytogenetics Conferences ESHG and ACC with 39 Scientific Presentations and Posters Highlighting the Utility of the Optical Genome Mapping Workflow

May 29, 2024

Bionano Announces Private Placement of Senior Secured Notes in Debt Restructuring that Improves Balance Sheet

May 27, 2024

Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy

May 20, 2024

Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis

May 8, 2024

Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress

May 7, 2024

Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024

April 30, 2024

Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing

April 23, 2024

Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing

April 10, 2024

Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

April 3, 2024

Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics

April 2, 2024

Bionano Announces 9 Poster Presentations and Introduces New High Throughput Stratys™ System at the American Association for Cancer Research Annual Meeting

April 1, 2024

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

March 18, 2024

Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System

March 6, 2024

Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024

March 4, 2024

Bionano to Report Fourth Quarter and Year End 2023 Financial Results and Host a Conference Call and Webcast on March 5, 2024

February 27, 2024

Bionano Announces Amendment to Debt Financing Arrangement to Extend Cash Runway

February 27, 2024

Bionano Announces Publication of a Study that Applied OGM to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer

January 24, 2024

Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing

January 23, 2024

Bionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping

January 22, 2024

Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

January 18, 2024

Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing

January 10, 2024

Bionano Announces 2024 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

January 9, 2024

Bionano Reports Preliminary Fourth Quarter and Full-Year 2023 Results

January 7, 2024

Calls in 2024

Decks in 2024